William Blair Lifts Target on Idenix (IDIX) to $14 Following Removal of Clinical Hold

William Blair's Katherine Xu boosted her price target on shares of Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) by 40 percent from $10 to $14 in an earlier research note Friday. Xu maintains an Outperform rating on Idenix Pharma.

Although Idenix shares are down more than 12 percent this afternoon amid an update from Gilead (Nasdaq: GILD) on its '7977, Idenix announced this morning the removal of a clinical hold on its IDX184. In an earlier note from Xu, the analyst said a buyout of Idenix would not happen until after the hold was removed.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Needham & Company Reiterates a 'Buy' on NetApp (NTAP); Solid 4Q Overshadowed by Conservative 1Q
• Nomura Securities Maintains a 'Buy' on Melco Crown Entertainment (MPEL); Raising PT and Estimates
• Barclays Cuts PT and Estimates on Dell (DELL); Apple's (AAPL) Momentum Proves Disrupting

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

William Blair

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter